Login / Signup

Antiviral Therapy of COVID-19.

Georgii GudimaIlya KofiadiIgor ShilovskiyDmitry KudlayMusa Khaitov
Published in: International journal of molecular sciences (2023)
Since the beginning of the COVID-19 pandemic, the scientific community has focused on prophylactic vaccine development. In parallel, the experience of the pharmacotherapy of this disease has increased. Due to the declining protective capacity of vaccines against new strains, as well as increased knowledge about the structure and biology of the pathogen, control of the disease has shifted to the focus of antiviral drug development over the past year. Clinical data on safety and efficacy of antivirals acting at various stages of the virus life cycle has been published. In this review, we summarize mechanisms and clinical efficacy of antiviral therapy of COVID-19 with drugs based on plasma of convalescents, monoclonal antibodies, interferons, fusion inhibitors, nucleoside analogs, and protease inhibitors. The current status of the drugs described is also summarized in relation to the official clinical guidelines for the treatment of COVID-19. In addition, here we describe innovative drugs whose antiviral effect is provided by antisense oligonucleotides targeting the SARS-CoV-2 genome. Analysis of laboratory and clinical data suggests that current antivirals successfully combat broad spectra of emerging strains of SARS-CoV-2 providing reliable defense against COVID-19.
Keyphrases
  • sars cov
  • coronavirus disease
  • respiratory syndrome coronavirus
  • healthcare
  • escherichia coli
  • current status
  • stem cells
  • big data
  • life cycle
  • gene expression
  • drug delivery
  • randomized controlled trial
  • clinical practice